Results 151 to 160 of about 1,494 (190)

Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations [PDF]

Annals of Hematology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare malignancy derived from plasmacytoid dendritic cells, can mimic both acute leukemia and aggressive T-cell lymphoma.
Jan-Henrik Mikesch, Ulrike Bacher, Evgenii Shumilov   +2 more
exaly   +5 more sources

Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Current Hematologic Malignancy Reports, 2016
The incorporation of Internet resources and the use of social media among patients, clinicians, advocates, and researchers in the field of hematology and oncology are growing in importance.
Andrew A Lane, Vikas Gupta, Naveen Pemmaraju   +2 more
exaly   +2 more sources

Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview

Hematology Reports, 2023
Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCNs) are a rare, highly aggressive hematological malignant neoplasm that primarily involve the skin, bone marrow, lymph nodes and even extra-nodal sites.
Emilio Bellitti, Giuseppe Ingravallo, Francesco Gaudio   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Promising results with tagraxofusp in BPDCN

Lancet Oncology, The, 2019
Elizabeth Gourd
exaly   +3 more sources

Managing BPDCN in the context of severe hyperbilirubinemia: a case study

Leukemia and Lymphoma
Francisco Vega, Naveen Pemmaraju, Hagop Kantarjian   +2 more
exaly   +3 more sources

Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Blood, 2015
Abstract Blastic plasmacytoid dendritic cell neoplasm is a clonal disease derived from precursors of plasmacytoid dendritic cells (pDC). It is a rare neoplasm involving the skin which may or may not be associated from the outset with a leukemic component.
Poret, Eve, Delettre, Fanny Angelot, Biichle, Sabeha, Roogy, Anne, Benazet, Louis, Pagadoy, Maider, Vidal, Chrystelle, Leroux, Franck, Harriverl, Veronique, Ferrand, Christophe, Salaun, Veronique, Benseddik, Zehaira, Guy, Julien, Jacob, Marie Christine, Roumier, Christophe, Feuillard, Jean, Vila, Liliana, Baseggio, Lucile, Plesa, Adriana, Arnoulet, Christine, Benet, B., Drénou, Bernard, Cannard, Veronique Latger, Béné, Marie-Christine, Ticchioni, Michel, Lusina, Daniel, Bardet, Valerie, Tavernier, Magalie L. E. Garff, Macintyre, Elizabeth, Asnafi, Vahid, Noguera, Maria Elena, Bouyer, Sabrina, Lafon, Carine Lecoq, Roussel, Mikael, Jardin, Fabrice, Solly, Françoise, Campos, Lydia, Galoisy, Anne, Arnaud, Anne, Daliphard, Sylvie, Geneviève, Franck, Lacroix, Romaric, Schillinger, Françoise, Seilles, Estelle, Binda, Delphine, Deconinck, Eric, Saas, Philippe, Ottou, Francine Garnache   +47 more
openaire   +2 more sources

Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Current Hematologic Malignancy Reports, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive hematologic malignancy that has heterogeneous presentation and can involve the skin, lymph nodes, and bone marrow. Recent advancements in our patho-biologic understanding of the disease have led to the development of new targeted therapies for BPDCN.
David Rizzieri, Naveen Pemmaraju, Minas P Economides   +2 more
exaly   +3 more sources

Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Expert Opinion on Pharmacotherapy, 2022
Unique among hematologic malignancies, blastic plasmacytoid dendritic cell neoplasm (BPDCN) affects multiple compartments including bone marrow, hematologic, lymphatic, dermatologic, and central nervous systems (CNS). Treating BPDCN is challenging, historically, as patients display refractoriness to chemotherapy and absence of long-term remissions in ...
Nathaniel R. Wilson, Naveen Pemmaraju
openaire   +2 more sources

Case Report: Early diagnostic precision matters: navigating therapeutic uncertainty in pediatric BPDCN illustrated by misdiagnosis sequelae and fleeting CAR-T response [PDF]

Frontiers in Pediatrics
Yuhua Qu
exaly   +2 more sources

Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN

Current Hematologic Malignancy Reports, 2017
The use of Twitter, one of the most commonly engaged social media platforms in the world, is increasing among the general public. Notably, this trend has also been observed among those involved in the healthcare field. With its ability to readily connect diverse groups of stakeholders in a given area of interest, Twitter has become a focal point for ...
Naveen, Pemmaraju, Audun, Utengen, Vikas, Gupta, Michael A, Thompson, Andrew A, Lane   +4 more
openaire   +2 more sources